Investigators found that the odds of locoregional recurrence of muscle-invasive bladder cancer following radical cystectomy depend on disease risk category.
Under the accelerated approval program, if a confirmatory trial does not show clinical benefit, the FDA can take steps to remove the drug or indication.
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Researchers analyzed data from patients with metastatic urothelial cancer to determine whether tumor mutation burden was associated with immune-related AEs among patients treated with immune checkpoint inhibitors.
Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
A retrospective analysis evaluated the incidence of ONJ in patients who received VEGF-TKIs or immune-oncology therapy for mRCC and bone-targeted therapies for bone metastases.
A retrospective analysis sought to determine the effect of hypertension on overall survival, response, and progression-free survival in patients with mRCC.
A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
Patients with metastatic urothelial carcinoma have significantly longer overall survival when treated with a combination of radiotherapy and chemotherapy compared with chemotherapy alone, a study found.